Thiamine deficiency in oncology: Clinical insights from two cases of Wernicke's encephalopathy.

Natl Med J IndiaJan 1, 2026

Ahmet Burak Agaoglu, Ferhat Ekinci, Atike Pinar Erdogan et al.

✦ AI-curated · Sources linked

Case in brief

Two patients with cancer and significant malnutrition and weight loss developed neurological presentations consistent with Wernicke’s encephalopathy (WE). The diagnosis was based on clinical findings and magnetic resonance imaging. Both patients improved after immediate intravenous thiamine treatment, with supportive care also provided. The report highlights WE as a potentially reversible complication in oncology patients.

What made this case unusual

The cases draw attention to WE in patients with cancer, where malnutrition and weight loss may be overlooked as risk factors and the diagnosis may be under-recognised.

Diagnostic / clinical pearl

In a patient with cancer and substantial malnutrition or weight loss, consider WE when neurological deficits arise; clinical assessment and MRI supported diagnosis in these cases.

Why it matters

The reported neurological deficits responded to intravenous thiamine, underscoring the importance of timely recognition of a potentially reversible condition.

Source

Published in Natl Med J India. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.